STOCK TITAN

Profound Medical Corp. - $PROF STOCK NEWS

Welcome to our dedicated page for Profound Medical news (Ticker: $PROF), a resource for investors and traders seeking the latest updates and insights on Profound Medical stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Profound Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Profound Medical's position in the market.

Rhea-AI Summary
Profound Medical Corp (NASDAQ:PROF; TSX:PRN) announced its participation in the Stifel 2023 Healthcare Conference to provide an update on the Company’s business. The presentation will be broadcast live and archived on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
conferences
-
Rhea-AI Summary
Profound Medical Corp. announced that the use of HCPCS C code, C9734, has been extended for use in the Ambulatory Surgical Center setting, and MRI-Monitored Transurethral Ultrasound Ablation (TULSA) of prostate tissue has been assigned device-intensive status. The ASC extension will go into effect on January 1, 2024. This decision by CMS allows hospitals and ASCs performing the TULSA procedure on Medicare patients to utilize the temporary C code, C9734.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.8%
Tags
none
-
Rhea-AI Summary
Profound Medical Corp. reported financial results for Q3 2023, with revenue of $1.7 million, a 40% increase in recurring revenue compared to Q3 2022. The company received FDA clearance for its TULSA AI Thermal Boost module. Total operating expenses decreased by 18% to $7.6 million. Net loss for Q3 2023 was $5.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.8%
Tags
Rhea-AI Summary
Profound Medical Corp. to announce third quarter 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
-
Rhea-AI Summary
Profound Medical Corp. provides additional details on Analyst & Investor Day event
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
-
Rhea-AI Summary
Profound Medical Corp. receives FDA clearance for its Thermal Boost module for use with TULSA-PRO®, enabling customized ablation in prostate cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
Rhea-AI Summary
Profound Medical Corp. to host Analyst & Investor Day event on October 13, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Profound Medical Corp. to present business update at Cantor Global Healthcare Conference on September 26, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
conferences
-
Rhea-AI Summary
Profound Medical Corp. establishes an at-the-market equity program to issue and sell up to US$30,000,000 of common shares. The TSX has conditionally approved the listing of the Common Shares. The Company intends to use the net proceeds for continued commercialization and development of its medical systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.5%
Tags
none
Rhea-AI Summary
Profound Medical Corp. reported financial results for Q2 2023, with a 38% increase in recurring revenue compared to Q2 2022. The company expects increased U.S. TULSA adoption and recurring revenue growth for the remainder of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
Profound Medical Corp.

Nasdaq:PROF

PROF Rankings

PROF Stock Data

179.80M
22.21M
8.71%
41.01%
1.32%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
Mississauga

About PROF

an inside out approach to prostate ablation profound medical is a canadian medical device company that has developed a unique and minimally invasive procedure to ablate the prostate gland in prostate cancer patients. profound’s novel technology combines real-time mr imaging with transurethral therapeutic ultrasound and closed-loop thermal feedback control. it provides a highly precise treatment tailored to patient-specific anatomy and pathology. this method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. the potential of this technology is currently being demonstrated in clinical trials. for more information, visit profoundmedical.com